

## Special Issue

# Advances in Targeted Therapy for Hematological Malignancies

### Message from the Guest Editor

Advances in targeted therapy for hematological malignancies have revolutionized treatment, providing new hope for patients with blood cancers. These therapies specifically target molecular and genetic abnormalities in cancer cells, minimizing damage to normal cells and reducing side effects compared to traditional chemotherapies. Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) treatment, and chemo-free regimens are under investigation for B-cell precursor acute lymphoid leukemia. Bruton's tyrosine kinase (BTK) inhibitors are effective in different B-cell, indolent, non-Hodgkin lymphomas. Monoclonal antibodies targeting CD20 on B-cells and CD38 on plasma cells, are now essential in treating B-cell lymphomas and multiple myeloma. Additionally, bispecific T-cell engagers (BiTEs) and chimeric antigen receptor (CAR) T-cell therapies have shown remarkable success in refractory and relapsed acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). These innovations highlight a shift towards personalized medicine in hematology, aiming to enhance the efficacy and scope of targeted therapies.

---

### Guest Editor

Dr. Andrea Visentin

Department of Medicine-DIMED, Hematology Unit, University of Padova, 35128 Padova, Italy

---

### Deadline for manuscript submissions

closed (31 March 2025)



## Targets

---

an Open Access Journal  
by MDPI



[mdpi.com/si/207625](https://mdpi.com/si/207625)

### *Targets*

Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[targets@mdpi.com](mailto:targets@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[targets](https://mdpi.com/journal/targets)





# Targets

an Open Access Journal  
by MDPI



[mdpi.com/journal/  
targets](https://mdpi.com/journal/targets)



## About the Journal

### Message from the Editor-in-Chief

*Targets* is an Open access journal devoted to the fast publication of the latest achievements in bio-detection and therapy. It provides important supports for the development of the related interdisciplinary areas of chemistry, life science, biomedicine, material science, and environment science, particularly in new drug development, disease diagnosis, early warning and targeted therapy, life process study, food and environment safety monitoring, quality control of products, forensic medicine, and even anti-terrorism.

---

### Editor-in-Chief

Prof. Dr. Huangxian Ju  
State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.9 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the second half of 2025).

#### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.